原发性肝癌化疗用药的现状与展望

姚连昌; 杨仁杰

原发性肝癌化疗用药的现状与展望

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3246
- HTML全文浏览量: 3
- PDF下载量: 1814
- 被引次数: 0
出版历程
- 出版日期: 2005-01-20

摘要

HTML全文

参考文献(17)

[1] AndoE , YamashitaF , TanakaM , etal.Anovelchemotherapyforadvancedhepatocellularcarcinomawithtumorthrombsisofthemaintrunkoftheportalvein[J].Cancer, 1997, 79∶1890-1896.

[2] 丁立, 马鸿飞.氟脲嘧啶脱氧核苷治疗肿瘤新进展[J].国外医学肿瘤分册, 1999, 26 (4) ∶206-2081.

[3] LlovetJM , RuffP , TassppoulosN , etal.AphaseⅡtrialoforale niluracil/5-fluououracilinpatientswithinoperablehepatocellularcar cinoma[J].EurJCancer, 2001, 37 (11) ∶1352-1358.

[4] ZhangXD , WangWL .Establishmentofanapoptoticmodelinducedbyadriamycininhumannepatocellularcarcinoma[J].ZhonghuaZhongliuZazhi (ChinJOncol) , 1997, 19 (4) ∶260-263.

[5] FavouletP , CercueilJP , FaureP , etal.IncreasedcytotoxicityandstabilityofLipiodol-pirarubicinemulsioncomparedtoclassicaldox orubicin-Lipiodol:potentialadvantageforchemoembolizationofunre sectablehepatocellularcarcinoma[J].Anti-CancerDrugs, 2001, 12 (10) ∶801-806.

[6]石珊, 杨小红, 罗以, 等.肝动脉注射以THP +DDP为主的药物治疗不能手术切除的肝癌[J].中国肿瘤临床, 1997, 24 (2) ∶157-161.

[7]韦长元.顺铂化疗后大肝癌的病理研究[J].肝胆外科杂志, 1997, 5 (1) ∶21-23.

[8] KamadaK , NakanishiT , KitamotoM , etal.Long-termprognosisofpatientsundergoingtranscatheterarterialchemoembolizationforun resectablehepatocellularcarcinoma:comparisonofcisplatinlipiodolsuspensionanddoxorubicinhydrochlorideemulsion[J].JournalofVas cular&InterventionalRadiology, 2001, 12 (7) ∶847-854.

[9] JeromeA , Jean-MarieT , MarineG -G , etal.Combinationoftopotecanandoxliplatinininoperablehepatocellularcancer patients[J].AmJClinOncol, 2002, 25 (2) ∶198-203.

[10] JunjiF , HiroshiI, MitsuoS , etal.Pilotstudyoftranscatheterarte rialchemoembolizationwithdegradablestarchmicrospheresinpatientswithhepatocellularcarcinoma[J].AmericanJournalofClinicalOncolo gy, 2003, 26 (2) ∶159-164.

[11] YangTS , WangCH , HsiehRK , etal.Gemcitabineanddoxoru bicinforthetreatmentofpatientswithadvancedhepatocellularcarci noma:aphaseⅠ-Ⅱtrial[J].AnnalsofOncology, 2002, 13 (11) ∶1771-1778.

[12] CapizziRN , HannHL , FreenyKJ , etal.Gemcitabine (G) , ami fostine (A) , andcisplatin (P) (GAP) treatmentforunresectablehepa tocellularcarcinoma (HCC) [J].AmSocClinOncol, 2000, 19∶285-287.

[13] TaiebJ, BonyhayL , GolliL , etal.Gemcitabineplusoxaliplatinininoperablehepatocellularcarcinoma (HCC ) :Acomparisonoftwoschedules[J].AnnalsofOncol, 2002, 13 (supp15) ∶196-197.

[14] JeongYY , MitchellDG , HannH -WL , etal.Hepatocellularcarci nomaaftersystemicchemotherapy:Gadolinium-enhancedMRmea surementofnecrosisbyvolumehistogram[J].JournalofComputerAssistedTomography, 2001, 25 (4) ∶624-628.

[15]YasujiK , KazunoriK , MakotoO , etal.Systemiccombinedchemotherapywithlowdoseof5-fluorouracil, cisplatin, andinter feron-[alpha]foradvancedhepatocellularcarcinoma:A pilotstudy[J].DigestiveDiseases&Sciences, 2003, 48 (5) ∶877-881.

[16] JunjiF , HiroshiI, MitsuoS , etal.Pilotstudyoftranscatheterarte rialchemoembolizationwithdegradablestarchmicrospheresinpatientswithhepatocellularcarcinoma[J].AmericanJournalofClinicalOncolo gy, 2003, 26 (2) ∶159-164.

[17] LeungTWT , YuS , JohnsonPJ, etal.PhaseⅡstudyoftheeffica cyandsafetyofcisplatin-epinephrineinjectablegeladministeredtopatientswithunresectablehepatocellularcarcinoma[J].JournalofClinicalOncology, 2003, 21 (4) ∶652-658.

施引文献

资源附件(0)

访问统计